AGP Picks
View all

Cimzia market to nearly double by 2030 as autoimmune demand rises

Nov. 2, 2026
Cimzia market to nearly double by 2030 as autoimmune demand rises
By AI, Created 14:30 UTC, Nov 02, 2026, AGP -

The global Cimzia market is projected to grow from $3.57 million in 2025 to $4.19 million in 2026, then reach $7.94 million by 2030, according to The Business Research Company. Growth is being driven by rising autoimmune disease cases, wider biologic use, and expanding reimbursement and diagnosis rates.

Why it matters: - Cimzia demand is tied to the growing treatment need for autoimmune diseases, especially rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. - The market’s projected expansion signals continued opportunity for biologic therapies that target inflammation more precisely than conventional treatments. - Faster growth in Asia-Pacific and continued dominance in North America point to shifting demand across major healthcare markets.

What happened: - The Business Research Company released its Cimzia Market Report 2026, covering the global market outlook from 2026 to 2035. - The report estimates the Cimzia market will rise from $3.57 million in 2025 to $4.19 million in 2026. - The report projects the market will reach $7.94 million by 2030. - The forecast implies a 17.6% CAGR from 2025 to 2026 and a 17.3% CAGR through 2030. - North America held the largest share of the global Cimzia market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Historical growth has been supported by approval of TNF inhibitors, higher autoimmune disease prevalence, limits of conventional treatments, specialist prescribing patterns, and greater biologic use in hospitals. - Future growth is expected to come from better biologic treatment protocols, higher diagnosis rates, biosimilar competition, greater patient preference for targeted therapies, and improved reimbursement coverage. - Cimzia, or certolizumab pegol, is a PEGylated monoclonal antibody that targets tumor necrosis factor, or TNF, to reduce inflammation and immune damage. - The drug is commonly used in moderate to severe rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. - A free sample of the report is available here. - The full report is available here. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis.

Between the lines: - Rising rheumatoid arthritis prevalence is a core demand driver for Cimzia because more diagnosed patients expand the pool for targeted treatment. - Arthritis WA projected in February 2024 that rheumatoid arthritis cases in Australia could reach about 212,136 men and 362,137 women by 2025, with further increases expected by 2040. - Aging populations also support demand because older adults are more likely to develop chronic inflammatory conditions. - The Population Reference Bureau projected the number of Americans age 65 and older would rise from 58 million in 2022 to 82 million by 2050, a 47% increase. - That age group’s share of the U.S. population is expected to rise from 17% to 23% over the same period. - Broader adoption of self-administered biologics suggests patients are valuing convenience and flexibility in chronic disease management.

What's next: - Market growth will likely depend on how quickly biologic treatment access expands and whether reimbursement keeps pace with demand. - The Asia-Pacific region may take on a larger role if healthcare investment and autoimmune disease awareness continue rising. - Biosimilar competition could shape pricing and market share over the next several years. - The company says the updated 2026 report is built to help readers track market hotspots and future technology trends.

The bottom line: - Cimzia sits in a market with strong long-term growth prospects as autoimmune disease treatment demand, biologic adoption, and aging populations continue to expand.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Investor World Review

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Investor World Review

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.